Still waiting for Israeli vaccination as cases and hospitalisations increase - OPID News

Our people in Diaspora News



Thursday, 14 January 2021

Still waiting for Israeli vaccination as cases and hospitalisations increase

 Still waiting for Israeli vaccination as cases and hospitalisations increase 


• Israel has given first dose of the Pfizer jab to almost 20 percent of its population

• Preliminary studies show that the vaccine cuts transmission, not just symptoms

• Expert warned initial studies not enough to conclude transmissions are stopped 

•  Data from hundreds of thousands of people offers extensive view of efficacy

• But experts have warned that people must stay vigilant despite having first dose

• Two other studies were also done, with varying results. One found the vaccine cuts infection risk by 60 percent, while another found it was cut by 33 percent

• Full 95 percent immunity is only achieved when a person is given second dose

Initial studies of data from Israel's world-beating vaccination drive suggest that the first dose of the Pfizer jab curbs coronavirus infections by up to 50 percent after 14 days. 

The news, announced by a top official from Israel's Health Ministry, offers a ray of hope to the rest of the world as initial studies point to the vaccine not only stopping symptoms, but cutting the risk of infection as well. 

In turn that has raised hopes that the vaccine will stop transmission of the virus, meaning the vaccination programs will have an even more dramatic effect on cutting coronavirus case rates. 

However Israel is still waiting for that effect to kick in despite vaccinating 20% of its population, with coronavirus rates in the country at their highest level ever and around 9,000 people infected a day.  Hospitalisations are also yet to fall with a record 1,102 people in hospital with coronavirus in Israel.  

The vaccine takes up to two weeks to provide full protection, and Israel is expecting to see new hospitalisations fall soon.   

That would mean that the vaccine would have an even more dramatic effect on 

With Israel rolling out the world's fastest vaccination programme, giving the first dose to almost 20 percent of its population, studies of hundreds of thousands of people offer perhaps the most extensive real-world data on the vaccine's efficacy. 

Sharon Alroy-Preis, head of the Health Ministry’s public health department, announced the 50 per cent figure to Channel 12 news, though cautioned that results are preliminary and need to be treated with caution.

Separately, two pieces of research by healthcare providers Maccabi and Calit showed infections dropped by 60 per cent and 33 per cent, respectively, after a first dose of vaccine.

The preliminary studies, which examined hundreds of thousands of patients, were both reported in Israeli media, though the data behind them has not been released to the public meaning no explanation has been given about the discrepancy in their figures.

Health minister Yuli Edelstein has warned Israelis to remain cautious even after a first dose of vaccine, amid concerns they could still catch the disease. 

On Tuesday, Israel saw daily Covid-19 infections and active cases reach all time-highs. On Tuesday, Israel reported 9,997 new cases - its highest in a single 24 hours - and 46 deaths, after recording a record 67 deaths on Monday

Israel is well ahead of other countries in its vaccine drive, administering 23.66 doses per 100 people, as of January 14. The second highest rate has been achieved by the UAE, with 14.1 per 100 people. In comparison, the UK has administered 4.52 per 100 people

Initial studies of data from Israel's vaccination drive suggest that the first dose of the Pfizer jab curbs coronavirus infections by up to 50 percent after 14 days. Pictured: A woman gets vaccinated against the COVID-19 coronavirus in the Israeli-annexed Golan Heights

Dr. Sharon Alroy-Preis, head of the Health Ministry's public health department, stressed to Israel's Channel 12 that the research was preliminary, and highlighted the need for caution - even among those that have received the first dose of jab. 

Alroy-Preis noted that the data was not enough to conclude that the vaccine stops transmission of Covid-19, because it is believed that a person can still spread the virus to others for a limited time if it is still located in their nasal cavity. 

She added that nearly one-fifth of the more than 1,000 serious Covid-19 patients in the country had previously received the first does of the vaccine.

'Seventeen percent of the new serious cases today, or 180 cases, are after the first dose,' she told reporters.   

On Tuesday, Israel saw daily Covid-19 infections and active cases reach all time-highs, and despite the optimistic signs, the country's health minister also stressed there was still the need for extreme caution. 

The vaccine is only expected to give a person 95 percent immunity against Covid-19 a week after receiving the second dose of the vaccine. Rollout of the second dose in Israel is set to begin this week, according to The Times of Israel. 

Speaking to The Telegraph, Yuli Edelstein, the country's health minister, warned that there was still a risk of catching the virus within two weeks of being given the jab, saying that Israelis must stay vigilant.

'Those who are getting the first shot should still be very, very cautious about their behaviour, due to the partial resistance to the disease,' Mr Edelstein said. 

Israel has leaped ahead in the global vaccine race by squeezing every last dose out of its vaccine supplies and using its efficient health system to launch a 24/7 immunisation drive with military help. Pictured: Mass vaccination centre in Tel Aviv

'In my imagination, it's like the scene from the movie where you nearly escape the danger, and at the very last moment you catch a bullet.' 

He added: 'It shows what we have already known, which is that the full 95 per cent protection comes after two shots.' 

The two studies carried out by health maintenance organisations (HMOs) compiled the data from some 400,000 patients they treated (800,000 in total), with the reason behind the discrepancy (60 percent and 33 percent) currently unclear.

The Clalit study compared test results of a group of 200,000 people who had been given the vaccine to a sample of 200,000 Israelis who had not received the jab.

The full results of the study are yet to be released or peer reviewed. 

Israel's vaccination programme is so far the fastest in the world and has given the vaccine to more than two million people - around 20 percent of its population.

The programme runs 24/7, even on the Jewish holdy day of Shabbat, and is being boosted by hundreds of Israeli combat medics who have been culled in for duty.

Given that Pfizer's phase 3 trials only checked 40,000 people, the data from Israel's vaccination campaign could offer some of the best indicators for the vaccines effectiveness against the coronavirus.

The Times of Israel reports that the latest number given by officials was 1,910,330 - although Prime Minister Benjamin Netanyahu held a ceremonial event celebrating the 2 millionth vaccine on Tuesday.

No comments:

Post a Comment